» Articles » PMID: 11705986

Prevention of Porphyromonas Gingivalis-induced Oral Bone Loss Following Immunization with Gingipain R1

Overview
Journal Infect Immun
Date 2001 Nov 14
PMID 11705986
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The arginine gingipains RgpA and RgpB of Porphyromonas gingivalis are well-documented virulence factors of this organism. Structurally, RgpA and RgpB have nearly identical catalytic domains, while RgpA possesses an additional hemagglutinin domain. In this study, we examined the abilities of these proteins to elicit protection against P. gingivalis-mediated oral bone loss in a murine oral challenge model. Mice immunized subcutaneously with heat-killed P. gingivalis or purified RgpA or RgpB possessed elevated levels of P. gingivalis-specific immunoglobulin G; however, only the animals immunized with P. gingivalis whole cells or RgpA were protected from maxillary bone loss. These data suggest that immunization with RgpA stimulates the production of hemagglutinin domain-specific antibodies, which contribute to the prevention of P. gingivalis-mediated periodontal disease.

Citing Articles

Arginine-specific gingipains (RgpA/RgpB) knockdown modulates neutrophil machinery.

Tubero Euzebio Alves V, Alves T, Rovai E, Hasturk H, Van Dyke T, Holzhausen M J Oral Microbiol. 2024; 16(1):2376462.

PMID: 38988325 PMC: 11234918. DOI: 10.1080/20002297.2024.2376462.


Vaccine: Antigens and Mucosal Adjuvants.

Wang S, Yan T, Zhang B, Chen Y, Li Z Vaccines (Basel). 2024; 12(6).

PMID: 38932348 PMC: 11209493. DOI: 10.3390/vaccines12060619.


Pan-Genome Analysis of Oral Bacterial Pathogens to Predict a Potential Novel Multi-Epitopes Vaccine Candidate.

Rida T, Ahmad S, Ullah A, Ismail S, Tahir Ul Qamar M, Afsheen Z Int J Environ Res Public Health. 2022; 19(14).

PMID: 35886259 PMC: 9320593. DOI: 10.3390/ijerph19148408.


The effect of local application of thymoquinone, 's bioactive component, on bone healing in experimental bone defects infected with .

Bastug A, Tomruk C, Guzel E, Ozdemir I, Duygu G, Kutan E J Periodontal Implant Sci. 2022; 52(3):206-219.

PMID: 35775696 PMC: 9253281. DOI: 10.5051/jpis.2101360068.


Future Drug Targets in Periodontal Personalised Medicine-A Narrative Review.

Yadalam P, Kalaivani V, Fageeh H, Ibraheem W, Al-Ahmari M, Khan S J Pers Med. 2022; 12(3).

PMID: 35330371 PMC: 8955099. DOI: 10.3390/jpm12030371.


References
1.
Moritz A, Cappelli D, Lantz M, Holt S, Ebersole J . Immunization with Porphyromonas gingivalis cysteine protease: effects on experimental gingivitis and ligature-induced periodontitis in Macaca fascicularis. J Periodontol. 1998; 69(6):686-97. DOI: 10.1902/jop.1998.69.6.686. View

2.
Landi L, Amar S, Polins A, Van Dyke T . Host mechanisms in the pathogenesis of periodontal disease. Curr Opin Periodontol. 1997; 4:3-10. View

3.
Potempa J, Brassell D, Nelson D, Thogersen I, Enghild J, Travis J . Comparative properties of two cysteine proteinases (gingipains R), the products of two related but individual genes of Porphyromonas gingivalis. J Biol Chem. 1998; 273(34):21648-57. DOI: 10.1074/jbc.273.34.21648. View

4.
Genco C, Odusanya B, Potempa J, Travis J . A peptide domain on gingipain R which confers immunity against Porphyromonas gingivalis infection in mice. Infect Immun. 1998; 66(9):4108-14. PMC: 108493. DOI: 10.1128/IAI.66.9.4108-4114.1998. View

5.
Genco C, Van Dyke T, Amar S . Animal models for Porphyromonas gingivalis-mediated periodontal disease. Trends Microbiol. 1998; 6(11):444-9. DOI: 10.1016/s0966-842x(98)01363-8. View